-
11.
公开(公告)号:US08580794B2
公开(公告)日:2013-11-12
申请号:US12951344
申请日:2010-11-22
Applicant: George A. Doherty , Steven W. Elmore , Lisa A. Hasvold , Andrew J. Souers , Zhi-Fu Tao , Gary T. Wang , Le Wang , Robert Mantei , Todd M. Hansen
Inventor: George A. Doherty , Steven W. Elmore , Lisa A. Hasvold , Andrew J. Souers , Zhi-Fu Tao , Gary T. Wang , Le Wang , Robert Mantei , Todd M. Hansen
IPC: A61K31/407 , C07D401/12
CPC classification number: C07D471/04 , C07D491/052 , C07D519/00
Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
-
12.
公开(公告)号:US08563735B2
公开(公告)日:2013-10-22
申请号:US12631404
申请日:2009-12-04
Applicant: Milan Bruncko , Hong Ding , George A. Doherty , Steven W. Elmore , Lisa Hasvold , Laura Hexamer , Aaron Kunzer , Robert A. Mantei , William J. McClellan , Chang H. Park , Cheol-Min Park , Andrew M. Petros , Xiaohong Song , Andrew J. Souers , Gerard M. Sullivan , Zhi-Fu Tao , Gary T. Wang , Le Wang , Xilu Wang , Michael D. Wendt
Inventor: Milan Bruncko , Hong Ding , George A. Doherty , Steven W. Elmore , Lisa Hasvold , Laura Hexamer , Aaron Kunzer , Robert A. Mantei , William J. McClellan , Chang H. Park , Cheol-Min Park , Andrew M. Petros , Xiaohong Song , Andrew J. Souers , Gerard M. Sullivan , Zhi-Fu Tao , Gary T. Wang , Le Wang , Xilu Wang , Michael D. Wendt
IPC: C07D401/10 , C07D213/62 , C07D307/02
CPC classification number: C07D401/12 , A61K31/407 , A61K31/495 , A61K31/496 , A61K31/501 , A61K31/5377 , A61K45/06 , C07D209/08 , C07D209/32 , C07D211/58 , C07D211/96 , C07D213/64 , C07D215/20 , C07D217/16 , C07D231/56 , C07D235/26 , C07D241/04 , C07D249/04 , C07D295/125 , C07D295/14 , C07D295/155 , C07D309/04 , C07D309/14 , C07D401/06 , C07D403/06 , C07D405/06 , C07D405/12 , C07D405/14 , C07D413/06 , C07D417/12 , C07D471/04 , C07D487/04
Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 or Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which are expressed anti-apoptotic Bcl-2 protein.
-
13.
公开(公告)号:US20110118235A1
公开(公告)日:2011-05-19
申请号:US12859182
申请日:2010-08-18
Applicant: James Jeffry Howbert , Gregory Dietsch , Robert Hershberg , Laurence E. Burgess , George A. Doherty , C. Todd Eary , Robert D. Groneberg , Zachary Jones
Inventor: James Jeffry Howbert , Gregory Dietsch , Robert Hershberg , Laurence E. Burgess , George A. Doherty , C. Todd Eary , Robert D. Groneberg , Zachary Jones
IPC: A61K31/55 , C07D403/10 , A61P37/02
CPC classification number: C07D223/16 , A61K31/4025 , A61K31/55 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/06 , C07D403/10 , C07D403/14
Abstract: Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease.
Abstract translation: 提供了可用于通过Toll样受体TLR7和/或TLR8调节信号传导的组合物和方法。 组合物和方法可用于治疗或预防疾病,包括癌症,自身免疫性疾病,感染性疾病,炎性疾病,移植物排斥反应和移植物宿主病。
-
14.
公开(公告)号:US20110105463A1
公开(公告)日:2011-05-05
申请号:US13001201
申请日:2009-06-24
Applicant: Laurence E. Burgess , Christopher T. Clark , Adam Cook , Christopher P. Corrette , Robert Kirk DeLisle , George A. Doherty , Kevin W. Hunt , Todd T. Romoff
Inventor: Laurence E. Burgess , Christopher T. Clark , Adam Cook , Christopher P. Corrette , Robert Kirk DeLisle , George A. Doherty , Kevin W. Hunt , Todd T. Romoff
IPC: A61K31/397 , C07D311/02 , A61K31/352 , C07D405/12 , A61K31/4025 , C07D403/12 , A61K31/453 , A61K31/506 , A61K31/4725 , A61P37/00
CPC classification number: C07D311/58 , C07D311/04 , C07D405/12 , C07D407/12
Abstract: Compounds of Formula (I): in which A1, A2, W, L, G, R7a, R7b, R8, R9 and R10 have the meanings given in the specification, are DP2 receptor modulators useful in the treatment of immunologic diseases.
Abstract translation: 式(I)化合物:其中A1,A2,W,L,G,R7a,R7b,R8,R9和R10具有本说明书中给出的含义,是可用于治疗免疫疾病的DP2受体调节剂。
-
15.APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES 有权
Title translation: 用于治疗癌症和免疫和自发性疾病的病毒诱导剂公开(公告)号:US20100298323A1
公开(公告)日:2010-11-25
申请号:US12793413
申请日:2010-06-03
Applicant: Milan Bruncko , Yujia Dai , Hong Ding , George A. Doherty , Steven W. Elmore , Lisa Hasvold , Laura Hexamer , Aaron R. Kunzer , Robert A. Mantei , William J. McClellan , Chang H. Park , Cheol-Min Park , Andrew M. Petros , Xiaohong Song , Andrew J. Souers , Gerard M. Sullivan , Zhi-Fu Tao , Gary T. Wang , Le Wang , Xilu Wang , Michael D. Wendt , Todd M. Hansen
Inventor: Milan Bruncko , Yujia Dai , Hong Ding , George A. Doherty , Steven W. Elmore , Lisa Hasvold , Laura Hexamer , Aaron R. Kunzer , Robert A. Mantei , William J. McClellan , Chang H. Park , Cheol-Min Park , Andrew M. Petros , Xiaohong Song , Andrew J. Souers , Gerard M. Sullivan , Zhi-Fu Tao , Gary T. Wang , Le Wang , Xilu Wang , Michael D. Wendt , Todd M. Hansen
IPC: A61K31/496 , C07D405/12 , C07D405/14 , C07D413/14 , C07D413/12 , C07D295/155 , C07D403/14 , C07D401/12 , C07D417/14 , A61K31/5377 , A61K31/495 , A61P35/00 , A61P35/02
CPC classification number: C07D213/76 , A61K31/495 , A61K31/496 , A61K31/5377 , A61K45/06 , C07D209/08 , C07D211/06 , C07D211/58 , C07D213/74 , C07D213/84 , C07D231/56 , C07D235/06 , C07D277/24 , C07D295/14 , C07D295/30 , C07D309/04 , C07D309/32 , C07D401/14 , C07D403/12 , C07D405/12 , C07D405/14 , C07D413/12 , C07D417/12 , C07D471/04
Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
Abstract translation: 公开了抑制抗凋亡Bcl-2蛋白活性的化合物,含有化合物的组合物和治疗疾病的方法,其中表达抗凋亡Bcl-2蛋白。
-
公开(公告)号:US20100093730A1
公开(公告)日:2010-04-15
申请号:US12571862
申请日:2009-10-01
Applicant: Pramila A. Bhatia , George A. Doherty , Irene Drizin , Helmut Mack , Richard J. Perner , Andrew O. Stewart , Qingwei Zhang
Inventor: Pramila A. Bhatia , George A. Doherty , Irene Drizin , Helmut Mack , Richard J. Perner , Andrew O. Stewart , Qingwei Zhang
IPC: A61K31/5377 , C07D403/02 , C07D401/02 , C07D413/02 , A61K31/497 , A61K31/4439
CPC classification number: C07D487/10 , C07D207/27 , C07D207/48 , C07D209/52 , C07D211/76 , C07D211/96 , C07D241/08 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/06 , C07D403/12 , C07D409/14 , C07D413/06 , C07D413/12 , C07D413/14 , C07D417/12 , C07D471/04
Abstract: The present application relates to calcium channel inhibitors containing compounds of formula (I) wherein Ar1, Ar2, L1, L2, n, R1, R4, X and Y are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.
Abstract translation: 本申请涉及含有式(I)化合物的钙通道抑制剂,其中Ar1,Ar2,L1,L2,n,R1,R4,X和Y如说明书中所定义。 本申请还涉及包含这些化合物的组合物,以及使用这些化合物和组合物治疗病症和病症的方法。
-
17.(3,4-Disubstituted)Propanoic Carboxylates as Sip (Edg) Receptor Agonists 失效
Title translation: (3,4-二取代)丙酸羧酸酯作为Sip(Edg)受体激动剂公开(公告)号:US20080249093A1
公开(公告)日:2008-10-09
申请号:US10575790
申请日:2004-12-13
Applicant: Vincent J. Colandrea , George A. Doherty , Jeffrey J. Hale , Pei Huo , Irene E. Legiec , Leslie Toth , Petr Vachal , Lin Yan
Inventor: Vincent J. Colandrea , George A. Doherty , Jeffrey J. Hale , Pei Huo , Irene E. Legiec , Leslie Toth , Petr Vachal , Lin Yan
IPC: A61K31/5377 , C07D213/02 , A61K31/4439 , C07D271/06 , A61K31/4245 , C07D263/30 , C07D333/00 , A61P37/02 , C07D257/04 , C07D277/02 , C07D285/12 , A61K31/433 , C07D295/00
CPC classification number: C07D271/06 , A61K31/4245 , A61K31/427 , A61K31/443 , A61K31/506 , C07D285/12 , C07D413/04 , C07D413/10 , C07D413/14 , C07D417/04
Abstract: The present invention encompasses compounds of Formula I: as well as the pharmaceutically acceptable salts thereof. The compounds are S1P1/Edg1 receptor agonists and thus have immunosuppressive, anti-inflammatory and hemostatic activities by modulating leukocyte trafficking, sequestering lymphocytes in secondary lymphoid tissues, and enhancing vascular integrity. The invention is also directed to pharmaceutical compositions containing such compounds and methods of treatment or prevention.
Abstract translation: 本发明包括式I的化合物及其药学上可接受的盐。 化合物是S1P1 / 1 / Edg1受体激动剂,因此通过调节白细胞运送,隔离淋巴细胞在次级淋巴组织中并增强血管完整性具有免疫抑制,抗炎和止血活性。 本发明还涉及含有这些化合物和治疗或预防方法的药物组合物。
-
公开(公告)号:US08785445B2
公开(公告)日:2014-07-22
申请号:US13141675
申请日:2009-12-18
Applicant: Adam Cook , Kevin W. Hunt , Robert Kirk Delisle , Todd Romoff , Christopher T. Clark , Ganghyeok Kim , Christopher P. Corrette , George A. Doherty , Laurence E. Burgess
Inventor: Adam Cook , Kevin W. Hunt , Robert Kirk Delisle , Todd Romoff , Christopher T. Clark , Ganghyeok Kim , Christopher P. Corrette , George A. Doherty , Laurence E. Burgess
IPC: C07D405/12 , A61K31/4433 , C07D241/20 , A61K31/497 , A61K31/501 , A61P11/06 , A61P27/14 , A61P17/00 , A61P29/00
CPC classification number: C07D405/12 , C07D405/14 , C07D413/12 , C07D417/12
Abstract: Compounds of Formula I: (I) in which A, A1, R1, R7a, R7b, R8 and R10 have the meanings given in the specification, are DP2 receptor inhibitors useful in the treatment of useful in the treatment and prevention of immunologic diseases, allergic diseases such as asthma, allergic rhinitis and atopic dermatitis, and other inflammatory diseases mediated by prostaglandin D2 (PGD2). The compounds of Formula I may also be useful in treating diseases or medical conditions involving the Th2 T cell via production of IL-4, IL-5 and/or IL-13.
Abstract translation: 其中A,A1,R1,R7a,R7b,R8和R10具有本说明书中给出的含义的式I化合物:(I)是可用于治疗和预防免疫疾病的DP2受体抑制剂, 过敏性疾病如哮喘,过敏性鼻炎和特应性皮炎,以及由前列腺素D2(PGD2)介导的其他炎性疾病。 式I化合物还可用于通过产生IL-4,IL-5和/或IL-13来治疗涉及Th2T细胞的疾病或医学病症。
-
19.
公开(公告)号:US08569522B2
公开(公告)日:2013-10-29
申请号:US13001201
申请日:2009-06-24
Applicant: Laurence E. Burgess , Christopher T. Clark , Adam Cook , Christopher P. Corrette , Robert Kirk DeLisle , George A. Doherty , Kevin W. Hunt , Todd T. Romoff
Inventor: Laurence E. Burgess , Christopher T. Clark , Adam Cook , Christopher P. Corrette , Robert Kirk DeLisle , George A. Doherty , Kevin W. Hunt , Todd T. Romoff
IPC: C07D311/58 , A61K31/353
CPC classification number: C07D311/58 , C07D311/04 , C07D405/12 , C07D407/12
Abstract: Compounds of Formula (I): in which A1, A2, W, L, G, R7a, R7b, R8, R9 and R10 have the meanings given in the specification, are DP2 receptor modulators useful in the treatment of immunologic diseases.
Abstract translation: 式(I)化合物:其中A1,A2,W,L,G,R7a,R7b,R8,R9和R10具有本说明书中给出的含义,是可用于治疗免疫疾病的DP2受体调节剂。
-
20.BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES 有权
Title translation: 用于治疗癌症和免疫疾病的BCL-2-选择性病毒诱导剂公开(公告)号:US20100152183A1
公开(公告)日:2010-06-17
申请号:US12631404
申请日:2009-12-04
Applicant: Milan Bruncko , Hong Ding , George A. Doherty , Steven W. Elmore , Lisa Hasvold , Laura Hexamer , Aaron Kunzer , Robert A. Mantei , William J. McClellan , Chang H. Park , Cheol-Min Park , Andrew M. Petros , Xiaohong Song , Andrew J. Souers , Gerard M. Sullivan , Zhi-Fu Tao , Gary T. Wang , Le Wang , Xilu Wang , Michael D. Wendt
Inventor: Milan Bruncko , Hong Ding , George A. Doherty , Steven W. Elmore , Lisa Hasvold , Laura Hexamer , Aaron Kunzer , Robert A. Mantei , William J. McClellan , Chang H. Park , Cheol-Min Park , Andrew M. Petros , Xiaohong Song , Andrew J. Souers , Gerard M. Sullivan , Zhi-Fu Tao , Gary T. Wang , Le Wang , Xilu Wang , Michael D. Wendt
IPC: A61K31/5377 , A61P35/04 , A61K31/497 , A61K31/4439 , A61K31/415 , A61K31/405 , A61K31/18 , C07D413/02 , C07D413/12 , C07D413/14 , C07D401/12 , C07D235/04 , C07D209/04 , C07C311/00
CPC classification number: C07D401/12 , A61K31/407 , A61K31/495 , A61K31/496 , A61K31/501 , A61K31/5377 , A61K45/06 , C07D209/08 , C07D209/32 , C07D211/58 , C07D211/96 , C07D213/64 , C07D215/20 , C07D217/16 , C07D231/56 , C07D235/26 , C07D241/04 , C07D249/04 , C07D295/125 , C07D295/14 , C07D295/155 , C07D309/04 , C07D309/14 , C07D401/06 , C07D403/06 , C07D405/06 , C07D405/12 , C07D405/14 , C07D413/06 , C07D417/12 , C07D471/04 , C07D487/04
Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 or Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which are expressed anti-apoptotic Bcl-2 protein.
Abstract translation: 公开了抑制抗凋亡Bcl-2或Bcl-xL蛋白的活性的化合物,含有该化合物的组合物和治疗疾病的方法,其中表达抗凋亡Bcl-2蛋白。
-
-
-
-
-
-
-
-
-